Table 3.

Association of cumulative RC with CVD in hypertensive participants and non-hypertensive participants

Cum-RC	Case/Total	Incidence density, per 1000 person-years	Model 1	Model 2	Model 3
G4*(≥ 54.66 mg/dl)	257/3433	7.25	1.45(1.21,1.75)	1.30(1.08,1.57)	1.27(1.03,1.57)
G3*(39.57-54.65 mg/dl)	209/3724	5.42	1.05(0.87,1.28)	0.97(0.79,1.17)	0.95(0.78,1.17)
G2*(26.40-39.56 mg/dl)	203/3583	5.50	1.08(0.89,1.31)	1.01(0.83,1.23)	1.00(0.82,1.22)
G1*(< 26.40 mg/dl)	198/3609	5.32	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
G1(< 26.40 mg/dl)	317/3587	8.77	1.65(1.38,1.97)	1.28(1.06,1.53)	1.28(1.06,1.53)
G2(26.40-39.56 mg/dl)	348/3587	9.65	1.91(1.60,2.27)	1.39(1.16,1.67)	1.38(1.15,1.66)
G3(39.57-54.65 mg/dl)	354/3588	9.86	2.00(1.67,2.38)	1.44(1.20,1.72)	1.42(1.17,1.71)
G4(≥ 54.66 mg/dl)	425/3587	11.87	2.35(1.99,2.78)	1.67(1.40,1.99)	1.63(1.32,2.00)
P-trend			< 0.0001	< 0.0001	< 0.0001

G1*-G4*were participants without hypertension;G1-G4 were participants with hypertension

Model 1: adjusted for age and sex

Model 2: included variables in model 1 and further SBP, LDL-C, HDL-C, BMI, hs-CRP, eGFR, family history of CVD, smoking status, alcohol consumption, physical exercise habits, diabetes, the use of antihypertensive drugs, the use of glucose-lowering drugs, and the use of lipid-lowering drugs

Model 3: included variables in model 2 and further the RC at baseline